---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-22-000003"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2022-01-26T23:59:59+00:00"
generated_at: "2026-06-27T15:41:40.283538+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vertex reports Q4 2021 product revenue $2.07B (+27% YoY); guides 2022 revenue $8.4-$8.6B

## Summary
- Full-year 2021 product revenue $7.57B (+22% YoY); GAAP diluted EPS $9.01, Non-GAAP $13.02.
- Q4 2021 GAAP net income $770M ($3.00 diluted EPS); Non-GAAP $866M ($3.37).
- FY 2022 product revenue guidance $8.4-$8.6B; combined Non-GAAP R&D+SG&A $2.70-$2.75B.
- KAFTRIO approved in EU/UK for CF children 6-11; new reimbursement agreements in Spain and Netherlands.
- Pipeline: VX-147 AMKD Phase 2 POC met; VX-880 T1D Day 150 data shows insulin reduction; CTX001 enrollment complete.

## SEC filing metadata
- accession: 0000875320-22-000003
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2022-01-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532022000003/0000875320-22-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532022000003/vrtx-20220126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-22-000003
- JSON: https://secwatch.observer/filing/0000875320-22-000003.json
- Plain text: https://secwatch.observer/filing/0000875320-22-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.